List of Cantex Pharmaceuticals patents | 7 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11648235 Treatment of glioblastoma	Patent 11648235 was granted and assigned to Cantex Pharmaceuticals on May, 2023 by the United States Patent and Trademark Office.	‌ Cantex Pharmaceuticals	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	11648235	May 16, 2023
‌ US Patent 8734804 Treatment of myelosuppression	Patent 8734804 was granted and assigned to Cantex Pharmaceuticals on May, 2014 by the United States Patent and Trademark Office.	‌ Paringenix	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	8734804	May 27, 2014
‌ US Patent 10052346 Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids	Patent 10052346 was granted and assigned to Cantex Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.	‌ Cantex Pharmaceuticals	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	10052346	August 21, 2018
‌ US Patent 10322096 Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms	Patent 10322096 was granted and assigned to Cantex Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	‌ Cantex Pharmaceuticals	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	10322096	June 18, 2019
‌ US Patent 11229664 Treatment of myelosuppression	Patent 11229664 was granted and assigned to Cantex Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.	‌ Cantex Pharmaceuticals	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	11229664	January 25, 2022
‌ US Patent 9271999 Treatment of myelosuppression	Patent 9271999 was granted and assigned to Cantex Pharmaceuticals on March, 2016 by the United States Patent and Trademark Office.	‌ Cantex Pharmaceuticals	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	9271999	March 1, 2016
‌ US Patent 10905661 Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms	Patent 10905661 was granted and assigned to Cantex Pharmaceuticals on February, 2021 by the United States Patent and Trademark Office.	‌ Cantex Pharmaceuticals	‌ Cantex Pharmaceuticals	United States Patent and Trademark Office	10905661	February 2, 2021